Trinity Capital, an alternative asset manager, committed $15 million in growth capital to Cagent Vascular, a developer of serration technology for vessel dilation in endovascular interventions. This capital augments $45 million of equity financing led by US Venture Partners in 2024.
“We are excited to partner with Cagent Vascular as they continue to innovate and expand their platform of valuable solutions for physicians treating patients with peripheral artery disease,” Ryan Kaeding, managing director, life sciences at Trinity Capital, said.
“Cagent Vascular’s Serration technology has been used in over 20,000 procedures and offers a growing library of compelling clinical evidence. We’re confident this additional capital will help scale our commercial infrastructure and further accelerate clinical adoption,” Brian Walsh, chairman and CEO of Cagent Vascular, said. “Trinity Capital’s support is appreciated as we build a leading vascular company and make a difference in the lives of patients around the globe.”
